Targeting PI3K signalling in cancer: opportunities, challenges and limitations

By J. Engelman. Nature Reviews. Cancer, 2009

2,465 citations recorded by the source corpus.

Subfields: Molecular Biology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3acbdc7572897680890455ae7d56b974f3d120d0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pathology and Forensic Medicine

In Pulmonary and Respiratory Medicine

Citations in the corpus

ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics (2014, background): “These include mutation and/or amplification of the genes encoding the PI3K catalytic subunits p110a (PIK3CA) and p110b (PIK3CB), the PI3K regulatory subunit p85a (PIK3R1), the PI3K effectors AKT1, AKT2, and PDK1, and loss of the lipid phosphatases PTEN and INPP4B (reviewed in Engelman, 2009).”
Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. (2012, background): “The PI3K-Akt signaling pathway is one of the major contributors to cancer development because it promotes cancer cell growth, survival, and metabolism (Elstrom et al., 2004; Engelman, 2009).”
Targeting cancer metabolism: a therapeutic window opens (2011, background): “; consequently, mTOR inhibitors are increasingly being used in the clinic to treat various cancers, and many compounds targeting the PI3K pathway are in clinical developmen”
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. (2012, background): “In studies of PI3K pathway inhibitors, [(18)F]FDGPET may reflect pharmacodynamic effects of target inhibition as well as antitumor effects.(16) Similar to the profile of tumor radiologic response, decreases in tumor [(18)F]FDG uptake were most significant at BKM120 doses 100 mg/d, suggesting that th”
The molecular biology of head and neck cancer (2011, background): “Another important signalling pathway in cancer, including HNSCC, is the PI3K–PTEN–AKT pathway, which is reviewed in Ref”
The PI3K/AKT Pathway as a Target for Cancer Treatment. (2016, background): “To date, mainly class IA PI3Ks have been implicated in cancer (1).”
Molecular mechanisms of cancer development in obesity (2011, background): “Activation of these receptors results in the phosphorylation of the IRS proteins, which activate the oncogenic RAS–MAPK and PI3K–AKT pathway”
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “The phosphatidylinositol 3-kinase (PIK3CA) pathway is one of the most commonly altered in SCC with PIK3CA mutation and amplification as well as loss of the PTEN tumour suppressor gene (4,153).”
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches (2012, background): “Finally, the PI3K and the MAPK pathways converge on the B cell leukemia 2 homology domain 3 (BH3) family of proteins, which regulate apoptosis [51].”